Journal profile · PHARMACOLOGY & PHARMACY
Journal of Pharmaceutical Innovation
ISSN 1872-5120 · eISSN 1939-8042 · Springer US · UNITED STATES · 4 issues per year · Founded 2006
Journal of Pharmaceutical Innovation: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.23; hybrid open access; APC about USD 3,990; median 107 days to acceptance (139 articles, last 24 months); community-reported acceptance: easy; 384 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Pharmaceutical Innovation is published by Springer US and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Advanced Drug Delivery Systems, Drug Solubulity and Delivery Systems and Advancements in Transdermal Drug Delivery, together about 45.4% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
The Journal of Pharmaceutical Innovation is the official journal of the International Society for Pharmaceutical Engineering (ISPE). It is an international, peer-reviewed journal dedicated to publishing high-quality scientific research in all areas of the pharmaceutical sciences and allied sciences. The journal serves as a comprehensive innovation resource for professionals and researchers in the field. The journal's broad scope includes: Pharmaceutics Nanotechnology Biopharmaceutics Industrial pharmacy Pharmacognosy Medicinal chemistry Pharmacology Pharmaceutical regulatory affairs Preclinical and clinical trials of innovative new drugs and drug formulations Pharmaceutical intellectual property Materials science Product design Process design, optimization, automation and control Facilities Information management Regulatory policy and strategy Supply chain developments The journal welcomes original research articles, invited review articles, case reports, short communications, letters to the editor, and commentaries on topics of current interest. Manuscripts that focus on pharmaceutical innovation, novel drug delivery approaches, quality management, regulatory pathways, and other emerging areas within the pharmaceutical field are particularly encouraged. Submissions with clinical, technological, regulatory, or practical implications that can further pharmaceutical research and development are also within the scope of the journal. Through a rigorous peer-review process and rapid publication, the journal aims to effectively disseminate significant scientific findings to a global audience of researchers, academics, and professionals in the pharmaceutical sciences and related industries.
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Editor-in-chief Robert LodderPublisher website
Editorial board by country: 1 in mainland China (about 4%); most named United States 20, Mainland China 1, United Kingdom 1, Japan 1, Italy 1 (28 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics16.6%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics16.2%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics12.5%
- Nanoparticle-Based Drug DeliveryMaterials Science6%
- Analytical Methods in PharmaceuticalsChemistry4.2%
- Crystallization and Solubility StudiesMaterials Science4.2%
- Computational Drug Discovery MethodsComputer Science3.9%
- Analytical Chemistry and ChromatographyChemistry3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
INSPECEmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.23LetPub ·
- Impact factor (publisher) 2025
- 2.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.1Publisher website ·
- CiteScore 2026-06
- 3.5LetPub ·
- SJR 2026-06
- 0.37LetPub ·
- SNIP 2026-06
- 0.63LetPub ·
- h-index
- 25LetPub ·
- h-index
- 48OpenAlex ·
- i10-index
- 407OpenAlex ·
- 2-year mean citedness
- 1.16OpenAlex ·
- Self-citation rate
- 7.7%LetPub ·
- Share of gold OA articles
- 12.35%LetPub ·
Volume
- Articles per year
- 374LetPub ·
- Downloads per year (publisher) 2025
- 241,700Publisher website ·
Articles by year OpenAlex count · 2,055 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 772 | 108 | 254 |
| 2025 | 384 | 51 | 774 |
| 2024 | 95 | 17 | 424 |
| 2023 | 104 | 21 | 788 |
| 2022 | 97 | 17 | 797 |
| 2021 | 79 | 18 | 1,020 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
107 daysMedian, submission to acceptance · P25–P75 76 days – 147 days
- Acceptance to online
- median 19 days (158 articles)
- Submission to online
- median 129 days
- Sample
- 139 articles with submission and acceptance dates (1,172 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to first decision
- 9 daysPublisher website ·
- Peer review
- Single anonymous peer review, Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,990 / EUR 3,090 / GBP 2,690 | — | — | |
| Publisher website | No APC | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Manuscript length
- ≤ 8,000 words
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted9
- case studyEditorial, Perspectives, Case Studies, Research Letters, Research Articles, Reviews Back to topLength not stated
- editorialSingle-blind peer review This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review proce…Length not stated
- hypothesisNote: For additional information, please view the Editorial Manager (EM)- Author Guide available from ISPE Publications. Editorial Editorial articles provide a …Length not stated
- letterEditorial, Perspectives, Case Studies, Research Letters, Research Articles, Reviews Back to topLength not stated
- opinionNote: For additional information, please view the Editorial Manager (EM)- Author Guide available from ISPE Publications. Editorial Editorial articles provide a …Length not stated
- perspectiveEditorial, Perspectives, Case Studies, Research Letters, Research Articles, Reviews Back to topLength not stated
- research articleEditorial, Perspectives, Case Studies, Research Letters, Research Articles, Reviews Back to topLength not stated
- research lettersThese are short papers reporting results that are of genuinely broad interest, but that for one reason or another do not make a sufficiently complete story to j…Length not stated
- reviewEditorial, Perspectives, Case Studies, Research Letters, Research Articles, Reviews Back to topLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Preprints, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
Manuscript submission implies originality, not under consideration elsewhere, and approval by co-authors and responsible authorities Model summary
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Permission required for previously published material Model summary
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Journal of Pharmaceutical Innovation, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review Single-blind peer review
Single-blind peer review Model summary
This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review process for these articles is the same as the peer review process of the journal in general. Additionally, if a guest editor authors an article in their issue/collection, they will not handle the peer review process.
Source ↗Publisher website ·- Preprints
4 to 6 keywords required Model summary
Please provide 4 to 6 keywords which can be used for indexing purposes.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer US
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- 4 issues per year
- Founded
- 2006
- ISSN
- 1872-5120
- Electronic ISSN
- 1939-8042
- Society / sponsor
- International Society for Pharmaceutical Engineering
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
FAQ
Frequently asked questions about Journal of Pharmaceutical Innovation
What CAS zone is Journal of Pharmaceutical Innovation in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Pharmaceutical Innovation is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Pharmaceutical Innovation?
The latest impact factor listed by LetPub is 2.23; CiteScore 3.5, h-index 48.
How long does peer review take at Journal of Pharmaceutical Innovation?
Based on the dates recorded on 139 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 107 days (interquartile range 76–147 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Pharmaceutical Innovation?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Manuscript length: ≤ 8,000 words; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Pharmaceutical Innovation based?
Of the 28 board members whose country the journal's board page names, 1 (about 4%) are in mainland China; the countries named most often are United States (20), Mainland China (1) and United Kingdom (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Pharmaceutical Innovation?
According to LetPub and DOAJ records, Journal of Pharmaceutical Innovation is indexed in SCIE and Scopus. The journal's website also lists INSPEC and Embase; that list has not been checked against each database.
Is Journal of Pharmaceutical Innovation open access, and what is the APC?
Journal of Pharmaceutical Innovation is a hybrid journal. For open-access publication: APC about USD 3,990.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .